Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside.
On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated, highlighting continued progress across the company’s clinical pipeline. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year. OPUS-2 has already begun participant dosages, and OPUS-3 is set to start in Q1 of 2026. Both studies are expected to deliver results in the first half of 2027.
Pressmaster/Shutterstock.com
On January 7, Needham analyst Joseph Stringer raised the price target for Vaxcyte Incorporated from $90 to $110 and maintained a Buy rating on the stock. This results in more than 100% upside at the prevailing level.
Stringer’s rating is backed by the inclusion of the stock on the firm’s Conviction List, highlighting it as a Top Pick for 2026 after replacing Phathom Pharmaceuticals (PHAT). The analyst shared his view that the strongly positive Phase 2 data for VAX-31 reduce risk ahead of the Phase 3 readout, which is expected in the fourth quarter of 2026. He believes the company’s pneumococcal vaccine retains best-in-class potential.
Vaxcyte Incorporated is a company developing next-generation vaccines to protect against serious bacterial diseases. Currently a clinical-stage company, Vaxcyte Inc. deploys innovative synthetic methods and advanced chemistry to produce complex, high-fidelity vaccines that contain enhanced immunological benefits.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
This article is originally published at Insider Monkey.
